Hope Rugo

534 total citations
36 papers, 232 citations indexed

About

Hope Rugo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Hope Rugo has authored 36 papers receiving a total of 232 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Hope Rugo's work include Advanced Breast Cancer Therapies (20 papers), Cancer Treatment and Pharmacology (16 papers) and Breast Cancer Treatment Studies (9 papers). Hope Rugo is often cited by papers focused on Advanced Breast Cancer Therapies (20 papers), Cancer Treatment and Pharmacology (16 papers) and Breast Cancer Treatment Studies (9 papers). Hope Rugo collaborates with scholars based in United States, United Kingdom and Spain. Hope Rugo's co-authors include Roger J. Jackman, Michael D. Lagios, Melvin J. Silverstein, Kathy Schilling, Suzanne Klimberg, Steven E. Harms, Robert R. Kuske, Michael N. Linver, Shawna C. Willey and Pat W. Whitworth and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Clinical Cancer Research.

In The Last Decade

Hope Rugo

34 papers receiving 221 citations

Peers

Countries citing papers authored by Hope Rugo

Since Specialization

Citations

This map shows the geographic impact of Hope Rugo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hope Rugo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hope Rugo more than expected).

Fields of papers citing papers by Hope Rugo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hope Rugo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hope Rugo. The network helps show where Hope Rugo may publish in the future.

Co-authorship network of co-authors of Hope Rugo

This figure shows the co-authorship network connecting the top 25 collaborators of Hope Rugo. A scholar is included among the top collaborators of Hope Rugo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hope Rugo. Hope Rugo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial 2025 ·Annals of Oncology ·Erik N. Mayer, (unknown), M.V. Martín, Gregory A. Vidal, Luca Moscetti, (unknown), Adam Brufsky, William J. Gradishar, Andreas Schneeweiß, Naoki Niikura, (unknown), Marcos E. Alfie, Kwang Suk Lee, Sobia Khan, M Feldman, (unknown), Linda Lam, (unknown), (unknown), Hope Rugo	2
2	Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial 2025 ·Breast Cancer Research ·Roberto A. Leon‐Ferre, (unknown), Christina Yau, (unknown), (unknown), Gillian L. Hirst, Nola M. Hylton, Jane Perlmutter, Angela DeMichele, Douglas Yee, Laura van ‘t Veer, Hope Rugo, W. Fraser Symmans, (unknown), Laura J. Esserman, (unknown)	1
3	Redefining clinical trial strategic design to support drug approval in medical oncology 2025 ·Annals of Oncology ·Gabriele Antonarelli, José Manuel Pérez-García, María Gión, Hope Rugo, (unknown), (unknown), Sara A. Hurvitz, Nadia Harbeck, Sara M. Tolaney, Giuseppe Curigliano, (unknown), Javier Cortés	1
4	Abstract PO2-14-09: Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2- metastatic breast cancer (mBC): the ELAINE 2 study 2024 ·Cancer Research ·Senthil Damodaran, Massimo Cristofanilli, Matthew P. Goetz, Ciara C. O’Sullivan, (unknown), Hope Rugo, Daniel G. Stover, Seth A. Wander, (unknown), Paul V. Plourde, David Portman, (unknown)	1
5	Abstract PO4-06-07: Efficacy and safety of futibatinib in patients with locally advanced/metastatic triple-negative breast cancer harboring FGFR2 gene amplification: final results from the phase 2, open-label FOENIX-MBC2 study 2024 ·Cancer Research ·(unknown), Nisha Unni, Senthil Damodaran, Hope Rugo, Timothy Crook, Thomas Bachelot, Federico Piacentini, Héctor Soto Parrà, Ian E. Krop, (unknown), (unknown), (unknown), Nicholas C. Turner, Fabrice André	0
6	Abstract PO5-21-09: Clinical outcomes by age subgroups in the phase 3 TROPiCS-02 study of sacituzumab govitecan vs treatment of physician’s choice in HR+/HER2‒ metastatic breast cancer 2024 ·Cancer Research ·Aditya Bardia, Peter Schmid, Sara M. Tolaney, Frederik Marmé, Javier Cortés, T. Valdez, Hao Wang, Wendy Verret, Hope Rugo	3
7	Abstract PS12-08: MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib/II, study of fulvestrant ± atezolizumab and abemaciclib triplet treatment in patients metastatic disease 2024 ·Cancer Research ·Kyung Hae Jung, Seock‐Ah Im, Denise A. Yardley, Sara A. Hurvitz, Keun Seok Lee, Amir Sonnenblick, Shlomit Strulov Shachar, Antoinette R. Tan, Elizabeth Comen, Einav Nili Gal‐Yam, Adam Brufsky, Hope Rugo, Jing Zhu, Kelly DuPree, (unknown), Fiona Young, Richard B. Schwab, Edward Cha, Melinda L. Telli	2
8	Abstract P3-01-14: Real-world treatment patterns of Palbociclib plus an aromatase inhibitor or aromatase inhibitor alone for metastatic breast cancer in the Flatiron database 2023 ·Cancer Research ·Hope Rugo, Xianchen Liu, Benjamin Li, (unknown), Connie Chen, Rachel M. Layman, Adam Brufsky	1
9	Abstract OT2-01-03: ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with metastatic breast cancer (mBC) 2023 ·Cancer Research ·Hope Rugo, Aditya Bardia, Javier Cortés, Giuseppe Curigliano, Erika Hamilton, Sara A. Hurvitz, Sibylle Loibl, Simona Scartoni, Tarek Sahmoud, Krzysztof Grzegorzewski, Nassir Habboubi, Joyce O’Shaughnessy	10
10	Abstract P4-09-12: Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From BYLieve Study Cohorts A and B 2023 ·Cancer Research ·Dejan Juric, Nicholas C. Turner, Sherene Loi, Fabrice André, Stephen Chia, Komal Jhaveri, Patrick Neven, Rebecca Dent, Eva Ciruelos, Mukta Joshi, (unknown), (unknown), (unknown), Hope Rugo	1
11	Abstract GS5-04: Identification of symptoms that are associated with irAEs in the I-SPY clinical trial 2023 ·Cancer Research ·Amrita Basu, (unknown), Michelle Melisko, Ruixiao Lu, Hongmei Yu, Christina Yau, Smita Asare, (unknown), Rebecca Shatsky, Claudine Isaacs, Angela DeMichele, Dawn L. Hershman, Rita Nanda, Mi‐Ok Kim, Laura J. Esserman, Hope Rugo	1
12	Abstract P5-05-05: Monitoring for response and recurrence in neoadjuvant-treated hormone receptor-positive HER2-negative breast cancer by personalized circulating tumor DNA testing 2023 ·Cancer Research ·Mark Jesus M. Magbanua, Hope Rugo, (unknown), (unknown), Gillian L. Hirst, Denise M. Wolf, Ruixiao Lu, Ekaterina Kalashnikova, Derrick Renner, (unknown), Minetta C. Liu, Christina Yau, Laura J. Esserman, Laura van ‘t Veer, Angela DeMichele	1
13	Abstract OT1-11-01: Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping 2023 ·Cancer Research ·Neelima Vidula, Senthil Damodaran, (unknown), Nora Horick, (unknown), Manali Bhave, Ami N. Shah, Leticia Varella, Vandana G. Abramson, Joseph A. Sparano, Leif W. Ellisen, Ishraq Alim, Harry Ostrer, Hope Rugo, Aditya Bardia	1
14	Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somaticBRCA1/2mutations identified by cell-free DNA: Genotyping based clinical trial 2022 ·Cancer Research ·Neelima Vidula, (unknown), (unknown), (unknown), Nora Horick, Senthil Damodaran, (unknown), Manali Bhave, Ami N. Shah, Minetta C. Liu, Joseph A. Sparano, Harry Ostrer, Hope Rugo, Leif W. Ellisen, Aditya Bardia	1
15	Abstract PD13-02: Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer 2022 ·Cancer Research ·Rachel M. Layman, Robert Wesolowski, Hyo S. Han, Jennifer M. Specht, Erica Stringer-Reasor, (unknown), Peter Kabos, Ingrid A. Mayer, Ulka N. Vaishampayan, Janice Lu, (unknown), Aditya Bardia, Anne F. Schott, Maysa Abu‐Khalaf, (unknown), Brian Sullivan, Igor Gorbatchevsky, Hope Rugo	8
16	Abstract OT2-17-01: Randomized, multicenter, international phase 3 ARTEST study to evaluate the efficacy and safety of enobosarm versus active control for the treatment of AR+ ER+ HER2- metastatic breast cancer in patients who progressed on a nonsteroidal aromatase inhibitor, fulvestrant and CDK 4/6 inhibitor 2022 ·Cancer Research ·Adam Brufsky, Hannah M. Linden, Hope Rugo, Charles L. Vogel, Joyce O’Shaughnessy, Robert H. Getzenberg, K. Gary Barnette, Domingo Rodrı́guez, Mitchell S. Steiner, Erica L. Mayer	1
17	Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial 2019 ·Cancer Research ·Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Emanuel F. Petricoin, Lamorna Brown Swigart, Gillian L. Hirst, Smita Asare, Douglas Yee, Angela DeMichele, Hope Rugo, Olufunmilayo I. Olopade, Rita Nanda, Minetta C. Liu, Laura Esserman, Laura van ‘t Veer	3
18	PO112EFFICACY OF NEPA, THE FIRST COMBINATION ANTIEMETIC AGENT, IN PATIENTS WITH BREAST CANCER RECEIVING ANTHRACYCLINE/CYCLOPHOSPHAMIDE (AC) OR NON-AC CHEMOTHERAPY 2015 ·The Breast ·Hope Rugo, Matti Aapro, Giorgia Rossi, Giada Rizzi	2
19	Advocacy spurs innovation: promoting synergy between physical and biomedical sciences 2013 ·SHILAP Revista de lepidopterología ·Susan L. Samson, Irene Acerbi, (unknown), Valerie M. Weaver, Hope Rugo	3
20	Image-Detected Breast Cancer: State-of-the-Art Diagnosis and Treatment 2009 ·Journal of the American College of Surgeons ·Melvin J. Silverstein, Abram Recht, Michael D. Lagios, Ira J. Bleiweiss, Peter Blumencranz, (unknown), Steven E. Harms, (unknown), Roger J. Jackman, Suzanne Klimberg, Robert R. Kuske, Gary M. Levine, Michael N. Linver, Elizabeth A. Rafferty, Hope Rugo, Kathy Schilling, Debu Tripathy, Pat W. Whitworth, Shawna C. Willey	107

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact